Overview IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease Status: Withdrawn Trial end date: 2021-05-30 Target enrollment: Participant gender: Summary To explore the efficacy of Ivabradine for the treatment of microalbuminuria in patients with type 2 diabetes and coronary heart disease. Phase: Phase 3 Details Lead Sponsor: Nanjing First Hospital, Nanjing Medical University